Disparities in parental distress in a multicenter clinical trial for pediatric acute lymphoblastic leukemia

Puja J Umaretiya1,2,3,4,5, Victoria B Koch1, Yael Flamand6

  • 1Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Insights

Parents facing household material hardship during childhood cancer treatment experience significantly higher psychological distress. Early interventions targeting both psychosocial needs and material hardship are crucial for these families.

Area of Science:

  • Pediatric Oncology
  • Psychosocial Oncology
  • Health Disparities

Background:

  • Parental psychological distress impacts child cancer treatment outcomes.
  • Identifying predictors of parental distress is key for effective interventions.
  • Household material hardship (HMH) is a modifiable poverty exposure linked to parental distress.

Purpose of the Study:

  • To investigate the association between household material hardship (HMH) and severe psychological distress in parents of children with acute lymphoblastic leukemia (ALL).

Main Methods:

  • Secondary analysis of parent-reported data from the Dana-Farber ALL Consortium Trial 16-001.
  • Parents completed HMH surveys at enrollment (T0) and 6 months (T1).
  • Severe parental distress was defined using the Kessler-6 scale; multivariable models adjusted for ALL risk and single parent status.

Main Results:

  • One-third of parents (32%) reported HMH at T0.
  • HMH at T0 was associated with over twice the odds of severe psychological distress.
  • HMH at T1 was associated with over five times the odds of severe distress at T1.

Conclusions:

  • Parents with HMH experienced significantly increased psychological distress, worsening over time.
  • This highlights a high-risk population needing targeted psychosocial and HMH interventions.
  • Addressing HMH can mitigate disparities in well-being for families undergoing childhood cancer treatment.
Abstract

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K